Abstract: Prostate cancer is one of the most common cancers in the male. Nitric oxide (NO), a crucial biological messenger and effector molecule, is involved in the regulation of various physiological functions and closely related to many diseases when its level is abnormal in the body. Now the research on NO-donor drugs has drawn more and more attention. A few NO-donor drugs have been confirmed to have favorable anticancer activity and have the potential for further clinical development of anticancer therapy. Currently some NO-donor drugs have exhibited significant anti-tumor effect, including organic nitrates, nitroprusside, S-nitrosothiols, diazeniumdiolates and so on. By targeting NO release, NO donors drugs can directly kill tumor cells, induce apoptosis, strengthen the immune system, as well as inhibit tumor proliferation, invasion and metastasis, and enhance radio- and chemo-sensitivity of tumor cells. In this paper, recent progresses in the research on NO-donor drugs in prostate cancer are reviewed.